Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588795 | 0.73 | SMN1; SMN2 (0.38) | IDO1SMN1; SMN2 | |
| SCHEMBL20637281 | 0.72 | SMN1; SMN2 (0.41) | IDO1SMN1; SMN2 | |
| SCHEMBL20181538 | 0.71 | TLR8 (0.50) | TLR8SMN1; SMN2 | |
| SCHEMBL6301307 | 0.69 | CYP19A1 (0.49) | TLR8 | |
| SCHEMBL16380057 | 0.68 | KDM4A (0.41) | — | |
| SCHEMBL12432830 | 0.67 | MAPT (0.46) | SMN1; SMN2 | |
| SCHEMBL18325765 | 0.67 | TLR8 (0.42) | TLR8 | |
| SCHEMBL12967525 | 0.66 | AGBL2 (0.30) | — | |
| SCHEMBL28156465 | 0.63 | MAOA (0.38) | IDO1SMN1; SMN2 | |
| SCHEMBL20721715 | 0.62 | CCR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018090921-A1 | URAT1 INHIBITOR AND USE THEREOF | 江苏新元素医药科技有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | SLC14A1, SLC10A6, SLC10A1 | TLR8 3694/4885IDO1 2799/4885SMN1; SMN2 4134/4885 |
| US-10875865-B2 | URAT1 inhibitor and use thereof | SLC14A1, SLC10A6, SLC10A1 | TLR8 3694/4885IDO1 2799/4885SMN1; SMN2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.